Jaguar Health (JAGX) EBITDA Margin (2015 - 2026)
Jaguar Health (JAGX) posted quarterly EBITDA Margin of 50.23% for Q1 2026, up 47575.0% year-over-year from N/an in Q1 2025, and up 107.65% quarter-over-quarter from 656.63% in Q4 2025.
Jaguar Health (JAGX) EBITDA Margin (2015 - 2026) Analysis & Trends
Jaguar Health (JAGX) has reported EBITDA Margin for 12 consecutive years, with 50.23% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin rose 47575.0% year-over-year to 50.23%; the TTM figure through Mar 2026 stood at 88.96% (up 18837.0% YoY), while the FY2025 annual figure was 398.82%, down 13506.0% from the prior year.
- EBITDA Margin rose to 50.23% in Q1 2026 per JAGX's latest filing, from 656.63% in the prior quarter.
- Across five years, EBITDA Margin topped out at 50.23% in Q1 2026 and bottomed at 58770.0% in Q1 2022.
- Historically, EBITDA Margin has averaged 6140.83% across 5 years, with a median of 312.37% in 2023.
- Annual changes were most pronounced in 2022 — EBITDA Margin slumped 5804434 bps — and 2023, when it surged 3689222 bps.
- Jaguar Health's EBITDA Margin stood at 19643.75% in 2022, then soared by 98 bps to 328.57% in 2023, then climbed by 29 bps to 232.46% in 2024, then slumped by 182 bps to 656.63% in 2025, then surged by 108 bps to 50.23% in 2026.
- Business Quant data shows JAGX's EBITDA Margin at 50.23% in Q1 2026, 656.63% in Q4 2025, and 234.77% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.69 Bn | 130.84 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.29 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.79 Bn | 59.60 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 59.44 Bn | 54.31 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.92 Bn | 27.61 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.10 Bn | 9.71 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.33 Bn | 26.17 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 19.75% |
| 10 | Jaguar Health | 459,102.90 | -9.60 Mn | 19.11 Mn | 50.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.23% |
| Dec 31, 2025 | -656.63% |
| Sep 30, 2025 | -234.77% |
| Jun 30, 2025 | -268.78% |
| Mar 31, 2025 | -425.52% |
| Dec 31, 2024 | -232.46% |
| Sep 30, 2024 | -233.66% |
| Jun 30, 2024 | -264.50% |
| Mar 31, 2024 | -349.43% |
| Dec 31, 2023 | -328.57% |
| Sep 30, 2023 | -312.37% |
| Jun 30, 2023 | -308.41% |
| Mar 31, 2023 | -21,877.78% |
| Dec 31, 2022 | -19,643.75% |
| Sep 30, 2022 | -315.86% |
| Jun 30, 2022 | -221.81% |
| Mar 31, 2022 | -58,770.00% |
| Dec 31, 2021 | -520.29% |
| Sep 30, 2021 | -1,549.43% |
| Jun 30, 2021 | -3,055.41% |